Biomira, Merck KGaA Begin BLP25 Liposome Vaccine Phase II Safety Study

Biomira and Merck KGaA of Darmstadt, Germany, announced the start of a Phase II, single-arm, multicenter, open-label study of BLP25 Liposome Vaccine (L-BLP25).

The trial will assess the safety of the formulation of L-BLP25 that the companies expect to use in the upcoming Phase III study. This formulation incorporates manufacturing changes intended to secure the future commercial supply of the vaccine.

Enrollment of the 20-patient trial involving men and women with non-small cell lung cancer from eight clinical trial sites in Canada is expected to be completed in the third quarter of 2005, with initial results anticipated before the end of 2005.